Chronic Venous Occlusions Treatment Market Report 2026
Global Outlook – By Product (Devices, Drugs), By Application (Varicose Veins, Venous Stasis Ulcers, Edema, Deep Vein Thrombosis, Other Applications), By End User (Hospitals, Clinics, Ambulatory Surgery Centers, Trauma centers, Other End-Users) - Market Size, Trends, Strategies, and Forecast to 2030
Chronic Venous Occlusions Treatment Market Overview
• Chronic Venous Occlusions Treatment market size has reached to $7.15 billion in 2025 • Expected to grow to $10.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Obesity Rates Fuel Growth In The Chronic Venous Occlusion Treatment Market • Market Trend: Introduction Of Innovative Dual-Layer Venous Stent System For Chronic Venous Occlusion Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Chronic Venous Occlusions Treatment Market?
Chronic venous occlusion refers to the long-term blockage or obstruction of veins, often in the legs or arms, which can impede blood flow and lead to various health issues, including swelling, pain, and skin changes. The treatment is used to manage symptoms, slow down the progression of the disease, and prevent complications. The main types of products included in chronic venous occlusion treatment are devices and drugs. Devices are instruments, apparatuses, machines, or implants used to prevent, diagnose, or treat disease. Devices help to restore proper blood flow in chronic venous occlusion treatment and improve overall venous health, contributing to successful treatment outcomes. It is used for several applications, including varicose veins, venous stasis ulcers, edema, deep vein thrombosis, and others, by hospitals, clinics, ambulatory surgery centers, trauma centers, and others.
What Is The Chronic Venous Occlusions Treatment Market Size and Share 2026?
The chronic venous occlusions treatment market size has grown strongly in recent years. It will grow from $7.15 billion in 2025 to $7.6 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing prevalence of venous disorders, wider availability of endovascular treatment options, growth in hospital-based interventional procedures, rising awareness of chronic venous diseases, expanded use of anticoagulant therapies.What Is The Chronic Venous Occlusions Treatment Market Growth Forecast?
The chronic venous occlusions treatment market size is expected to see strong growth in the next few years. It will grow to $10.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing aging population base, rising demand for outpatient venous procedures, growing focus on early disease diagnosis, expansion of advanced imaging-assisted treatments, increasing adoption of next-generation venous devices. Major trends in the forecast period include increasing adoption of minimally invasive venous interventions, rising use of advanced venous stenting technologies, growing preference for combination device and drug therapies, expansion of image-guided endovascular procedures, enhanced focus on long-term occlusion management.
Global Chronic Venous Occlusions Treatment Market Segmentation
1) By Product: Devices, Drugs 2) By Application: Varicose Veins, Venous Stasis Ulcers, Edema, Deep Vein Thrombosis, Other Applications 3) By End User: Hospitals, Clinics, Ambulatory Surgery Centers, Trauma centers, Other End-Users Subsegments: 1) By Devices: Venous Stents, Catheters, Endovenous Laser Therapy (EVLT) Devices, Angioplasty Balloons 2) By Drugs: Anticoagulants, Thrombolytics, Anti-inflammatory Medications, Pain Management DrugsWhat Is The Driver Of The Chronic Venous Occlusions Treatment Market?
The increasing incidence of obesity is expected to propel the growth of the chronic venous occlusion treatment market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat, typically resulting in an individual having a body mass index (BMI) of 30 or higher. Chronic venous occlusion treatment can help control obesity-related symptoms like edema and skin changes by improving blood flow and reducing inflammation, contributing to better obesity management. For instance, in March 2023, according to the World Heart Federation, a Switzerland-based non-government global cardiovascular community, globally around 2.3 billion adults and children were obese or overweight, and with the current obesity trend, it is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Therefore, the growing incidence of obesity is driving the growth of the chronic venous occlusion treatment market.Key Players In The Global Chronic Venous Occlusions Treatment Market
Major companies operating in the chronic venous occlusions treatment market are Cardinal Health Inc., Bayer AG, Sanofi S.A., 3M Company, Bristol-Myers Squibb Company, Medtronic PLC, Becton, Dickinson and Company (BD), Stryker Corporation, Boston Scientific Corporation, Terumo Corporation, Ethicon Inc., Philips Medical Systems, Teleflex Incorporated, Cook Group Incorporated, Merit Medical Systems Inc., Integer Holdings Corporation, Penumbra Inc., Inari Medical, Argon Medical Devices Inc., AngioDynamics Inc., Rontis Corporation, Endologix, Richard Wolf GmbH, SIGVARIS AG, enVVeno Medical Corporation, LimFlow SA
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Chronic Venous Occlusions Treatment Market Trends and Insights
Major companies operating in the chronic venous occlusion treatment market are focused on developing innovative solutions, such as implantable medical devices indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI). An implantable medical device is a surgically placed device designed to remain inside the body for an extended period, often to diagnose, treat, or monitor medical conditions. For instance, in June 2024, Koninklijke Philips N.V. (Philips), a Netherlands-based technology company, launched the Duo Venous Stent System, an implantable medical device. The Duo Venous Stent System by Koninklijke Philips N.V. features a dual-layer design that enhances flexibility and radial strength for optimal vein support. Its advanced coating improves biocompatibility and minimizes thrombosis risk, while the precise delivery system ensures accurate placement in challenging anatomical conditions.What Are Latest Mergers And Acquisitions In The Chronic Venous Occlusions Treatment Market?
In February 2025, Stryker Corporation, a US-based medical technology company, acquired Inari Medical, Inc., for an undisclosed amount. With this acquisition, Stryker aims to expand into the high-growth peripheral vascular segment, strengthen its interventional portfolio, and accelerate innovation in minimally invasive vascular treatments. Inari Medical, Inc. is a US-based medical device company specializing in mechanical thrombectomy solutions for venous thromboembolism and other vascular conditions.
Regional Outlook
North America was the largest region in the chronic venous occlusions treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Chronic Venous Occlusions Treatment Market?
The chronic venous occlusion treatment market consists of revenues earned by entities by providing services such as magnetic resonance imaging (MRI), fluoroscopy, computerized tomography (CT) scanning, anticoagulation therapy, and surgical intervention. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic venous occlusion treatment market also includes sales of anticoagulants, thrombolytic agents, pain relievers, and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Chronic Venous Occlusions Treatment Market Report 2026?
The chronic venous occlusions treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic venous occlusions treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Chronic Venous Occlusions Treatment Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $7.6 billion |
| Revenue Forecast In 2030 | $10.08 billion |
| Growth Rate | CAGR of 7.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Product, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Cardinal Health Inc., Bayer AG, Sanofi S.A., 3M Company, Bristol-Myers Squibb Company, Medtronic PLC, Becton, Dickinson and Company (BD), Stryker Corporation, Boston Scientific Corporation, Terumo Corporation, Ethicon Inc., Philips Medical Systems, Teleflex Incorporated, Cook Group Incorporated, Merit Medical Systems Inc., Integer Holdings Corporation, Penumbra Inc., Inari Medical, Argon Medical Devices Inc., AngioDynamics Inc., Rontis Corporation, Endologix, Richard Wolf GmbH, SIGVARIS AG, enVVeno Medical Corporation, LimFlow SA |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |